Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

N-of-One to Provide Clinical Interpretation for Guardant360™ Tests

Published: Monday, May 19, 2014
Last Updated: Tuesday, May 20, 2014
Bookmark and Share
Breakthrough blood test enables next generation sequencing of solid tumor DNA.

N-of-One today announced an agreement with Guardant Health to provide clinical decision support for Guardant360™, a breakthrough blood test that enables next generation sequencing of solid tumor DNA. Financial terms of the agreement are not disclosed.

Guardant360 is the first pan-cancer blood test that helps oncologists prescribe the right treatments at the right time based on the changing genomics of a patient's cancer. The test uses trace fragments of tumor DNA that are shed into the bloodstream ("cell-free DNA") for reconstructing and sequencing a patient’s cancer to detect emergent alterations that can help oncologists better match patients to potential therapeutic options.

N-of-One’s clinical interpretation provides relevant biological and clinical knowledge related to the mutation profile of the identified tumor DNA, and links this state-of-the-art knowledge to relevant therapeutic strategies, including clinical trials, to support oncologists in making molecularly-informed, personalized treatment decisions.

"Guardant360 is the first comprehensive, non-invasive tumor sequencing test providing real-time answers," said Helmy Eltoukhy, Ph.D., Guardant Health's co-founder and chief executive officer. “Knowledge of genomic alterations in combination with potential therapies can be most helpful to an oncologist and the treatment of their patients."

“N-of-One provides diagnostic companies with best in class, state-of-the-art biological and clinical knowledge relevant to each test’s findings” said Chris Cournoyer, CEO of N-of-One. “Leveraging N-of-One clinical knowledge enables diagnostic companies to scale their test volumes in a cost effective manner.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos